OmniAb, Inc.

OmniAb, Inc. (Nasdaq: OABI) is a life sciences company specializing in proprietary antibody discovery platforms, which entered the public markets through a business combination with Avista Public Acquisition Corp. II, a blank-check vehicle sponsored by Avista Capital Partners that completed its IPO in 2021. Originally operating as a division of Ligand Pharmaceuticals, OmniAb was spun out and merged with the SPAC, with the transaction closing in October 2022, establishing OmniAb as an independent publicly traded entity. This Form 10-Q, filed in May 2022 under accession number 0001104659-22-063431, captures the company's financial position during the pre-close period of the pending transaction. Sign up at SpacDesk for full filings, deal timelines, and analytics on OmniAb and hundreds of other SPAC transactions.